Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
14 evidence topics · 10 sources
Management of darovasertib plus crizotinib toxicities through dose holds, dose reductions, dietary counseling, and expert-center linkage
Crizotinib label: patient counseling on hepatotoxicity, bradycardia, and blood pressure medications
Crizotinib label: patient counseling on vision disorders, drug interactions, and photosensitivity
Pharmacist-led interventions for oral anticancer therapy: systematic review and meta-analysis of 27 studies
“A total of 27 studies evaluating pharmacist-led interventions in patients receiving oral anticancer therapy were identified through systematic searches, including randomized controlled trials, non-randomized controlled trials, and cohort studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 11 pharmacist interventions distributed across four main domains, namely patient education and behavioral support, symptom and toxicity management, medication therapy management, and healthcare access support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis revealed that pharmacist interventions tend to improve medication adherence and treatment persistence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the impact on clinical endpoints and the incidence of drug-related problems remained heterogeneous.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: expert recommendations on liver value monitoring and the two major toxicities
“The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: symptomatic management of cytokine release in a 2026 systematic review
Tebentafusp: structured adverse event monitoring in community oncology practice
Tebentafusp: management of skin reactions
Immune checkpoint inhibitors: management of immune-related adverse events by grade
“The management of immune-related adverse events depends on their severity: in mild cases (grade 1), therapy can be continued with simple monitoring; in moderate cases (grade 2), therapy is temporarily suspended and oral corticosteroids are administered; in severe cases (grade 3 or 4), treatment is discontinued and high-dose corticosteroids are used, possibly with additional immunosuppressants such as infliximab for refractory colitis or mycophenolate for hepatitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response assessment with RECIST, tumor growth rate, and circulating tumor DNA
Early palliative and supportive care in the guideline
“Early integration of palliative care is internationally recommended to facilitate the transition from curative to palliative care and to individualise the intensity of care for patients with cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It may include psychological support, nutrition and palliative care support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surveillance for metastasis after treatment of the primary tumor at reference centers
“Prognostication and surveillance should be led by a specialist MTB with UM expertise in ophthalmology, liver imaging, surgery, medical oncology and supportive care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surveillance strategies should be managed at reference centres [III, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk-based surveillance imaging after treatment of the primary tumor: North American Delphi consensus
“Intermediate-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for 5 years, thereafter annually for at least 10 years from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for years 1–5 and every 6–12 months for years 6–10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In high-risk patients, the use of contrast-enhanced MRI abdomen is preferred over CT abdomen for surveillance of metastatic uveal melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there was agreement that low-risk patients warrant surveillance, no consensus was reached on the optimal approach for this group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote